Cephalosporin Market Report 2024: Size, Share, Trends, Growth Drivers, Forecast to 2033

Overview and Scope

Cephalosporin refers to a class of broad-spectrum, semisynthetic-lactam antibiotics that are the most widely prescribed class of antibiotics used to treat diseases caused by gram-positive and gram-negative bacteria, such as skin infections, strep throat, pneumonia, staph infections, tonsillitis, and bronchitis. Cephalosporins are especially useful for people allergic to penicillin, another common antibiotic.

Sizing and Forecast

The cephalosporin market size has grown steadily in recent years. It will grow from $17.04 billion in 2023 to $17.69 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to growing prevalence of bacterial infections, increasing antibiotic resistance, expanding surgical procedures and hospitalizations, rising awareness among healthcare professionals, regulatory support for antibiotic development..

The cephalosporin market size is expected to see steady growth in the next few years. It will grow to $20.29 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to escalating global burden of infectious diseases, emerging bacterial resistance, continued growth in surgical interventions and healthcare-associated infections, increasing demand for broad-spectrum antibiotics, evolving reimbursement policies influencing market dynamics.. Major trends in the forecast period include technological advancements, regulatory landscape, market expansion with advance solution, collaborations and partnerships..

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/cephalosporin-global-market-report

Segmentation & Regional Insights

The cephalosporin market covered in this report is segmented –

1) By Type: Branded, Generic
2) By Route Of Administration: Injection, Oral
3) By Application: Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, Sexually Transmitted Infection, Other Applications

Asia-Pacific was the largest region in the cephalosporin market in 2023. The regions covered in the cephalosporin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13402&type=smp

Major Driver Impacting Market Growth

The growing prevalence of infectious diseases is expected to propel the growth of the cephalosporin market going forward. Infectious diseases refer to illnesses caused by the invasion and multiplication of pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, which can be transmitted from one individual to another through various means that cause diseases such as tuberculosis, malaria, and flu. Infectious diseases drive the demand for cephalosporin antibiotics, which are commonly used to treat infectious diseases caused by bacterial pathogens and can be prescribed for various types of infections due to their crucial role in managing and combating bacterial infections. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,300 tuberculosis (TB) cases were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the growing prevalence of infectious diseases will drive the growth of the cephalosporin market.

Key Industry Players

Major companies operating in the cephalosporin market report are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Novartis AG, AbbVie Inc., AstraZeneca PLC, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Allergan PLC, Baxter International Inc., Eisai Co. Ltd., Macleods Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd., Shionogi & Co Ltd, Cipla Inc.., Hikma Pharmaceuticals PLC, Lupin Ltd., Zydus Lifesciences Ltd., Alkem Labs Ltd., Aurobindo Pharma Ltd., Fresenius Kabi, Aristo Pharmaceuticals Ltd, Accord Healthcare Ltd., Mankind Pharma Ltd., Qilu Anti Pharmaceutical Co. Ltd., Shandong Ruiying Pioneer Pharmaceutical Co. Ltd, Vansen Pharma Inc.</b

The cephalosporin market report table of contents includes:

1. Executive Summary
2. Cephalosporin Market Characteristics
3. Cephalosporin Market Trends And Strategies
4. Cephalosporin Market – Macro Economic Scenario
5. Global Cephalosporin Market Size and Growth
.
.
.
32. Global Cephalosporin Market Competitive Benchmarking
33. Global Cephalosporin Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Cephalosporin Market
35. Cephalosporin Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model